Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Clin Chem. 2019 Feb 15;65(5):653–663. doi: 10.1373/clinchem.2018.296780

Fig. 4. Plasma N-glycan levels in type I and type II CDG patients compared with normal controls.

Fig. 4.

(A), The overlays of plasma N-high mannose abundance (% total glycan) in type I CDG patients (red), type II CDG patients (blue), and 31 normal controls (gray). (B), Selected ratios between N-linked high mannose among type I CDG patients, type II CDG, and normal controls. (C), Plasma N-linked complexed glycan levels in type I CDG patients, type II CDG, and normal controls. (D), Plasma N-linked fucosylated and bisected N-glycan levels in type I CDG patients, type II CDG, and normal controls. The abundance of N-linked Man5 (A) and the ratio of Man5/Man9 (B), highlighted by blue rectangles, separate most CDG patients from the normal controls. Among complexed glycans, the abundance of 2 monogalactosylated glycans (highlighted by blue arrows) separates most patients with CDG from the normal controls (C). A fucosylated monoantennary glycan and a monogalactosylated glycan (highlighted by blue arrows) are representative plasma N-glycan markers that separate patients with CDG from normal controls.